Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms

Next Previous
X
Search
Trial Profile

A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVR 118 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Proof of concept
  • Acronyms RESCUE
  • Sponsors EOM Pharmaceuticals

    • Most Recent Events

    • 06 Sep 2023 Status changed from recruiting to completed, according to a EOM Pharmaceuticals media release.
    • 06 Sep 2023 Topline results presented in the EOM Pharmaceuticals Media Release.
    • 06 Sep 2023 According to a EOM Pharmaceuticals media release, the study was conducted at four different medical centers in the Brazilian states of Sao Paolo and Goaia. Due to challenges in in patient enrollment during the COVID-19 pandemic led to a reduction in eligible hospitalized patients. The redesigned trial enrolled a total of 23 patients eligible for evaluation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top